Results 171 to 180 of about 111,907 (307)

Endocan level and its association with glycemic and inflammatory indices in diabetic nephropathy. [PDF]

BMC Endocr Disord
Al-Mayahi LM, Al-Shammaree SAW.
europepmc   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg, Kasper Bonnesen, Morten Schmidt, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Mette Nørgaard, Reimar Wernich Thomsen   +7 more
wiley   +1 more source

Unveiling the immune microenvironment in diabetic nephropathy: from mechanisms to therapeutics. [PDF]

Front Immunol
Jiang T, Chen R, Chang J, Duan J, Wang Y, Sun Y, Chen X, Ma Y, Zhang L, Jiang H, Chen H.   +10 more
europepmc   +1 more source

Multi‐Parametric Magnetic Resonance Imaging to Assess Empagliflozin Effect on the Kidneys in People With Type 2 Diabetes Mellitus: A Pilot Clinical Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Empagliflozin is renoprotective in Type 2 diabetes mellitus (T2DM). Our primary aim was to assess empagliflozin's effect on glomerular filtration rate and renal vascular resistance using multiparametric MRI (MpMRI). Our secondary aim was to assess the impact of empagliflozin on additional MpMRI‐derived metrics including markers of tissue ...
Ruth P. Lim, Salma Qassin, Lucy McKenna, Emma Hornsey, Dominic Italiano, Leonid Churilov, Richard J. MacIsaac, Jas‐mine Seah, Elif I. Ekinci, The Austin EMPA‐MRI Study Group   +9 more
wiley   +1 more source

Analysis of Circulating and Urinary Levels of hsa-miRNA-770-5p in Diabetic Nephropathy. [PDF]

Biomolecules
Nikolov D, Nikolov G, Geneva-Popova M, Popova-Belova S, Naydenov M, Karusheva MG.   +5 more
europepmc   +1 more source

Abnormal Glycaemic Fluctuations Associated With Early Microvascular Changes in the Retina and Choroid of Nondiabetic Adults

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the association between continuous glucose monitoring (CGM)‐derived glycaemic variability indicators and early microvascular changes of the retina and choroid in nondiabetic individuals. Materials and Methods Community‐based individuals at high risk for type 2 diabetes (T2DM) underwent detailed assessments including oral ...
Yan Jiang, Liping Gu, Yuhang Ma, Yuan Qu, Hancong Wan, Kangjia Lv, Qian Zhu, Hao Zhou, Jian Sun, Fei Lu, Xiaowei Li, Yufei Wang, Jian Zhou, Kun Liu, Yufan Wang, Yinchen Shen   +15 more
wiley   +1 more source

Circadian Reprogramming of Protein Homeostasis and Glycolipid Metabolism in Diabetic Nephropathy. [PDF]

FASEB Bioadv
Li XQ, Cheng L, Chen TF, Ma YN, Wang LY, Li XH, Fu TY, Xiao J, Zhao ZZ.   +8 more
europepmc   +1 more source

Subgroups of Adult‐Onset Diabetes: A Prospective Follow‐Up Study of Progression of Insulin Resistance and Deficiency and Association With Liver Steatosis and Fibrosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen, Annemari Käräjämäki, Aki J. Käräjämäki, Samu Kurki, Liisa Hakaste, Olof Asplund, Johan Hultman, Kaj Lahti, Mikko Lehtovirta, Emma Ahlqvist, Tiinamaija Tuomi   +10 more
wiley   +1 more source

A case of giant renal angiomyolipoma and diabetic nephropathy with abnormalities in the genes TSC2 and HNF1B. [PDF]

CEN Case Rep
Sugimoto H, Sawa N, Oba Y, Mizuno H, Sekine A, Yamanouchi M, Tanaka K, Hasegawa E, Suwabe T, Wada T, Yokoyama T, Miki K, Nakamura Y, Ishii Y, Kono K, Ohashi K, Takazawa Y, Fujimaru T, Mori T, Sohara E, Ubara Y.   +20 more
europepmc   +1 more source

Dapagliflozin attenuates ferroptosis in diabetic nephropathy through activation of the Nrf2/HO‑1 signaling pathway. [PDF]

Int J Mol Med
Liu H, Zhang X, Cui Y, Xiong S, Huang L, Li M, Shao C, Hu X.   +7 more
europepmc   +1 more source